ABSTRACT
Hypertensive emergencies are critical conditions characterized by severe blood pressure (BP) elevations causing acute target organ damage. Despite advancements in hypertension management, these emergencies remain a significant clinical challenge, affecting 1–2% of hypertensive patients and often arising from poor disease control. This review integrates updated guidelines, emerging evidence, and treatment strategies to optimize outcomes. Pathophysiological mechanisms, including failure of autoregulation and renin–angiotensin–aldosterone system activation, contribute to endothelial dysfunction and microvascular injury. Effective management requires rapid, yet cautious BP reduction to prevent further organ damage while preserving perfusion. Intravenous antihypertensive agents, such as labetalol and nicardipine, are emphasized for their safety and efficacy. Comparative studies highlight nicardipine’s superior efficacy in achieving rapid BP control, whereas labetalol offers versatility with fewer cardiac side effects. In specific scenarios, such as ischemic stroke or preeclampsia, treatment is tailored to underlying conditions, reflecting guideline recommendations. Long-term outcomes depend on sustained BP control and the prevention of hypertensive-mediated organ damage. Emerging biomarkers provide insights into disease progression and potential therapeutic targets. Despite progress, research gaps remain in precision medicine and healthcare equity. Future efforts should focus on personalizing treatment and integrating advanced diagnostics to reduce morbidity and mortality in hypertensive emergencies.